期刊文献+

三种方案治疗晚期大肠癌近期疗效比较 被引量:4

Immediate effects of three different regimens in advanced colorectal cancers
下载PDF
导出
摘要 目的 :比较 5 FU/LV、L OHP +5 FU/LV及CPT 11+5 FU/LV治疗晚期大肠癌的疗效和毒副反应。方法 :采用三种方案对 6 5例患者进行研究 ,3周为一个疗程。 5 FU/LV方案为LV 2 0 0mg/d ,iv 2小时 ,第 1~ 5天 ;5 FU5 0 0mg/d ,iv第 1~ 5天 ;L OHP +5 FU/LV方案为L OHP 130mg/m2 iv第 1天 ,5 FU/LV用法同上 ;CPT 11+5 FU/LV方案为CPT 11180mg/m2 30分钟第 1天 ,5 FU/LV用法同上。至少化疗 2个疗程后进行评价。结果 :三种方案总体疗效分别为 13.33%、2 1.2 1%、11.76 % ;总体恶心、呕吐发生率分别为 4 0 .0 0 %、39.39%、17.6 5 % ;腹泻发生率分别为 13.33%、6 .0 6 %、2 9.4 1% ;骨髓抑制发生率分别为 2 6 .6 7%、2 4 .2 4 %、35 .2 9% ;神经毒性发生率分别为 0、15 .15 %、0 ;三种方案间均无显著性差异 (P >0 .0 5 )。结论 :三种方案治疗晚期大肠癌的近期疗效无明显差别 ,毒副反应发生率低 ,耐受好 。 Purpose:To compare the effect and toxicity of 5-FU/LV, L-OHP+5-FU/LV, CPT-11+5-FU/LV in advanced colorectal cancers.Methods:65 patients were entered into the study. All the regimens were repeated every 3 weeks. 5-FU/LV regimen was given as LV 200mg/d,iv 2h,d 1-5; 5-FU 500 mg/d, iv d 1-5. L-OHP+5-FU/LV regimen was given as L-OHP 130mg/m 2 iv d 1, and 5-FU/LV same to the above. CPT-11+5-FU/LV regimen was given as CPT-11 180mg /m 2 30min d 1 and 5-FU/LV same to the above. Results:The overall response rate was 13.33%, 21.21%, 11.76% respectively (P>0.05). The overall rate of nausea/vomiting was 40.00% ,39.39%,17.65% respectively(P>0.05); the rate of diarrhea was 13.33%,6.06%,29.41% respectively(P>0.05); the rate of bone marrow depression was 26.67% ,24.24%,35.29% respectively (P>0.05) and the rate of cold related dysesthesia was 0,15.15%,0 respectively (P>0.05).Conclusions:There was no difference in terms of both effect and toxicity among the three regimens. All of them were effective and could be well tolerated by advanced colorectal cancer patients.
出处 《中国癌症杂志》 CAS CSCD 2004年第3期265-267,共3页 China Oncology
关键词 大肠癌 氟尿嘧啶 亚叶酸钙 草酸铂 依立替康 colorectal cancers fluorouracil/leucovorin oxaliplatin irinotecan
  • 相关文献

参考文献9

  • 1管忠震,孙晓非,冯奉仪,金懋林,许立功,黄建瑾,冯继峰,隋广杰,谭华.依立替康 (Irinotecan ,CPT -11)治疗晚期大肠癌临床研究[J].癌症,1999,18(6):686-690. 被引量:63
  • 2Kouroussis C, Souglakos J, Kakolyris S,et al .Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study[J].Oncology,2001,61(1):36-41.
  • 3Zori Comba A, Blajman C, Richardet E,et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients[J]. Eur J Can
  • 4Lee JH, Lee JH, Kim TW ,et al. Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer[J]. J Korean Med Sci,2001,16(1):69-74.
  • 5Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)[J]. Eur J Cancer,2001,37(8):1000
  • 6Comella P, De Vita F, De Lucia L,et al. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma[J]. Ann Oncol,2000,11(4):461-468.
  • 7Maiello E, Gebbia V, Giuliani F,et al.5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group[J]. Ann Oncol,2000,11(8):1045-1051.
  • 8de Gramont A, Figer A, Seymour M,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol,2000,18(16):2938-2947.
  • 9Firvida JL, Irigoyen A, Vazquez-Estevez S,et al. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma[J].Cancer,2001,91(4):704-711.

共引文献62

同被引文献81

引证文献4

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部